Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: Results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee

Pain

Volumn 155, Issue 7, 2014, Pages 1245-1252

  Tiseo, Paul J ^a   Kivitz, Alan J ^b   Ervin, John E ^c   Ren, Haobo ^a   Mellis, Scott J ^a  

^a REGENERON PHARMACEUTICALS INC   (United States)

^b Altoona Center for Clinical Research   (United States)

^c Center for Pharmaceutical Research   (United States)

Author keywords

Anti NGF; Fasinumab; Nerve growth factor; Osteoarthritis; Pain; REGN475

Indexed keywords

FASINUMAB; PLACEBO; MONOCLONAL ANTIBODY; NERVE GROWTH FACTOR;

ABNORMAL LABORATORY RESULT; ABNORMAL SENSATION; ADULT; AGED; AREFLEXIA; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSESTHESIA; ELEVATED BLOOD PRESSURE; EXPLORATORY RESEARCH; FEMALE; HEADACHE; HUMAN; HYPERESTHESIA; HYPERREFLEXIA; HYPESTHESIA; HYPOKALEMIA; HYPOREFLEXIA; INFLUENZA; JOINT STIFFNESS; JOINT SWELLING; KNEE OSTEOARTHRITIS; KNEE PAIN; LIMB PAIN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MYALGIA; OUTCOME ASSESSMENT; PALLANAESTHESIA; PARALLEL DESIGN; PARESTHESIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REPEATED DRUG DOSE; RHINOPHARYNGITIS; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; WALKING; WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX; ANTAGONISTS AND INHIBITORS; COMPLICATION; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ARTHRALGIA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE GROWTH FACTOR; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 84902325269     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1016/j.pain.2014.03.018     Document Type: Article

References (28)

1. R. Altman, E. Asch, D. Bloch, G. Bole, D. Borenstein, K. Brandt, W. Christy, T.D. Cooke, R. Greenwald, M. Hochberg, D. Howell, D. Kaplan, W. Koopman, S. Longley, H. Mankin, D.J. McShane, T. Medsger, R. Meenan, W. Mikkelsen, R. Moskowitz, W. Murphy, B. Rothschild, M. Segal, L. Sokoloff, and F. Wolf Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee Arthritis Rheum 29 1986 1039 1049
2. J. Avouac, L. Gossec, and M. Dougados Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials Osteoarthritis Cartilage 15 2007 957 965
3. C. Barthel, N. Yeremenko, R. Jacobs, R.E. Schmidt, M. Bernateck, H. Zeidler, P.P. Tak, D. Baeten, and M. Rihl Nerve growth factor and receptor expression in rheumatoid arthritis and spondyloarthritis Arthritis Res Ther 11 2009 R82
4. N. Bellamy, W.W. Buchanan, C.H. Goldsmith, J. Campbell, and L.W. Stitt Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee J Rheumatol 15 1988 1833 1840
5. G. Burgess, and D. Williams The discovery and development of analgesics: new mechanisms, new modalities J Clin Invest 120 2010 3753 3759
6. M.S. Cepeda, F. Camargo, C. Zea, and L. Valencia Tramadol for osteoarthritis: a systematic review and meta-analysis J Rheumatol 34 2007 543 555
7. M. Chao, R. Rajagopal, and F.S. Lee Neurotrophin signaling in health and disease Clin Sci 110 2006 167
8. M.J. Elders The increasing impact of arthritis on public health J Rheumatol Suppl 60 2000 6 8
9. C.T. Hartrick, J.P. Kovan, and S. Shapiro The numeric rating scale for clinical pain measurement: a ratio measure? Pain Pract 3 2003 310 316
10. H. Hurst, and J. Bolton Assessing the clinical significance of change scores recorded on subjective outcome measures J Manipulative Physiol Ther 27 2004 26 35
11. F. Iannone, C. De Bari, F. Dell'Accio, M. Covelli, and V. Patella Lo Bianco G, Lapadula G. Increased expression of nerve growth factor (NGF) and high affinity NGF receptor (p140 TrkA) in human osteoarthritic chondrocytes Rheumatology 41 2002 1413 1418
12. A. Lanas A review of the gastrointestinal safety data - a gastroenterologist's perspective Rheumatology 49 Suppl. 2 2010 ii3 ii10
13. N.E. Lane, T.J. Schnitzer, C.A. Birbara, M. Mokhtarani, D.L. Shelton, M.D. Smith, and M.T. Brown Tanezumab for the treatment of pain from osteoarthritis of the knee N Engl J Med 363 2010 1521 1531
14. J.A. Markenson, J. Croft, P.G. Zhang, and P. Richards Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial Clin J Pain 21 2005 524 535
15. K.E. McNamee, A. Burleigh, L.L. Gompels, M. Feldmann, S.J. Allen, R.O. Williams, D. Dawbarn, T.L. Vincent, and J.J. Inglis Treatment of murine osteoarthritis with TrkAd5 reveals a pivotal role for nerve growth factor in non-inflammatory joint pain PAIN® 149 2010 386 392
16. S. Pezet, and S.B. McMahon Neurotrophins: mediators and modulators of pain Ann Rev Neurosci 29 2006 507 518
17. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43:1905-15.
18. M. Rihl, E. Kruithof, C. Barthel, F. De Keyser, E.M. Veys, H. Zeidler, D.T. Yu, J.G. Kuipers, and D. Baeten Involvement of neurotrophins and their receptors in spondyloarthritis synovitis: relation to inflammation and response to treatment Ann Rheum Dis 64 2005 1542 1549
19. M.C. Rowbotham What is a "clinically meaningful" reduction in pain? PAIN® 94 2001 131 132
20. F. Salaffi, A. Stancati, C.A. Silvestri, A. Ciapetti, and W. Grassi Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale Eur J Pain 8 2004 283 291
21. M.F. Seidel, M. Herguijuela, R. Forkert, and U. Otten Nerve growth factor in rheumatic diseases Semin Arthritis Rheum 40 2010 109 126
22. S.D. Skaper Nerve growth factor: a neurokine orchestrating neuroimmune-endocrine functions Mol Neurobiol 24 2001 183 199
23. S. Trelle, S. Reichenbach, S. Wandel, P. Hildebrand, B. Tschannen, P.M. Villiger, M. Egger, and P. Jüni Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis BMJ 342 2011 c7086
24. D.A. Walsh, D.F. McWilliams, M.J. Turley, M.R. Dixon, R.E. Fransès, P.I. Mapp, and D. Wilson Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis Rheumatology 49 2010 1852 1861
25. J.E. Ware, M. Kosinski, and S.D. Keller A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity Med Care 34 1996 220 233
26. J.J. Watson, S.J. Allen, and D. Dawbarn Targeting nerve growth factor in pain: what is the therapeutic potential? BioDrugs 22 2008 349 359
27. A.D. Woolf, and B. Pfleger Burden of major musculoskeletal conditions Bull World Health Organ 81 2003 646 656
28. G.D. Yancopoulos, P.C. Maisonpierre, N.Y. Ip, T.H. Aldrich, L. Belluscio, T.G. Boulton, M.H. Cobb, S.P. Squinto, and M.E. Furth Neurotrophic factors, their receptors, and the signal transduction pathways they activate Cold Spring Harb Symp Quant Biol 55 1990 371 379